ERBB2 and neoplasm: Antibodies can be designed to inhibit the activation signals in tumor cells (HER2, EGFR, CD38, RANKL), to block angiogenesis (VEGF), and to block the inhibitory signals in immune cells (CTLA4, PD1, PDL1).